Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice to "Biochar modulating soil biological health: A review" [Sci. Total Environ. 914 (2024) 169585].

The Science of the total environmentĀ·2026
Same author

MicroRNA profiling in serum and correlation with tumor tissue and clinicopathological parameters in periampullary carcinoma.

Annals of hepato-biliary-pancreatic surgeryĀ·2026
Same author

Evaluating an Online Training Program for Child Sexual Abuse Prevention in Schools: The Role of Training, Leadership, and Policy in Educator Awareness and Reporting.

Journal of child sexual abuseĀ·2026
Same author

Patterns of kidney supportive care referrals in a tertiary hospital in India: a six-year audit.

BMC nephrologyĀ·2026
Same author

Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada.

International journal of geriatric psychiatryĀ·2026
Same author

Alzheimer's disease drug development pipeline: 2026.

Alzheimer's & dementia (New York, N. Y.)Ā·2026

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.3K

The roles of biomarkers in Alzheimer's disease clinical trials.

Jeffrey Cummings1, Shailja Sharma2, G Andrea2

  • 1Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA; Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|December 25, 2025
PubMed
Summary

Biomarkers are crucial for Alzheimer's disease (AD) clinical trials, aiding decisions across development phases. They guide therapy selection and accelerate new treatments by measuring drug effects and disease progression.

Keywords:
Alzheimer's diseaseAmyloid imagingBiomarkerClinical trialsContext of usep-Tau 217

More Related Videos

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.3K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.9K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

751

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Biomarker Development

Background:

  • Biomarkers are vital for decision-making in Alzheimer's disease (AD) clinical trials.
  • Their contexts of use (COUs) span diagnosis, risk, pharmacodynamics, prognosis, prediction, monitoring, and safety.
  • Biomarker utility varies across clinical trial phases (1, 2, and 3).

Purpose of the Study:

  • To review the diverse roles and applications of biomarkers in AD drug development.
  • To highlight current and emerging biomarkers used in AD clinical trials.
  • To emphasize the integration of biomarker strategies throughout the drug development process.

Main Methods:

  • Review of current literature and practices in AD biomarker utilization.
  • Discussion of established biomarkers (e.g., amyloid/tau PET, fluid measures) and emerging technologies.
  • Exploration of data interrogation approaches like AI and machine learning for biomarker analysis.

Main Results:

  • Current pharmacodynamic biomarkers include amyloid/tau PET and fluid measures of AD pathology, neurodegeneration, inflammation, and synaptic plasticity.
  • AI and machine learning can enhance biomarker value through multimodal data integration.
  • Emerging biomarkers include proteomics, exosome assays, EEG, ocular measures, and digital biomarkers.

Conclusions:

  • Biomarkers are integral to informing critical decisions in AD drug development, including trial termination or advancement.
  • Effective biomarker strategies accelerate the development of effective therapies for AD.
  • Biomarkers are essential for identifying promising treatments and advancing therapeutic development for AD patients.